Intracellular messenger RNA in CD8+ T cells (mRNA (CD8+ T cell))

Intracellular messenger RNA (mRNA) in CD8+ T cells refers to the pool of coding RNA molecules within cytotoxic T lymphocytes that serve as templates for protein synthesis and represent a critical focal point for modern immunotherapy. CD8+ T cells are the primary effectors of the adaptive immune system responsible for identifying and destroying virally infected or malignant cells through the release of cytotoxic granules [1][2]. Therapeutic strategies targeting these mRNAs involve either the delivery of synthetic mRNA to induce the transient expression of therapeutic proteins—such as Chimeric Antigen Receptors (CARs) or stimulatory cytokines—or the use of antisense technologies to degrade endogenous mRNAs encoding inhibitory checkpoint proteins like PD-1 or CBL-B [3][4]. This approach allows for precise, non-integrative modulation of T-cell function, offering a safer and more flexible alternative to traditional gene therapies. Current clinical development focuses on using lipid nanoparticle (LNP) delivery systems to reprogram CD8+ T cells in vivo, offering potential treatments for cancer, chronic infections, and fibrotic conditions [1][3].

Other names

CD8+ T cell mRNACytotoxic T lymphocyte mRNAT-cell directed mRNA therapeuticsIntracellular mRNA targets

Translation of exogenous mRNA into functional proteins or silencing of endogenous mRNA transcripts via RNA interference.